E SciSparc Might Become The Next GW Pharmaceuticals

SciSparc's Revenue Potential

As mentioned above, SciSparc's cannabinoid-based drug development programs are targeting the treatment of Tourette Syndrome, Autism Spectrum Disorder, Epilepsy, Obstructive Sleep Apnea, Alzheimer's Disease, and pain management and each has multi-million-dollar revenue potential for SciSparc going forward.

SCI-110: Tourette's Syndrome

Tourette's syndrome is a genetic neuropsychiatric disorder, characterized by physical and vocal tics, and associated with the exclamation of obscene words or socially inappropriate remarks. Tics are repetitive and non-rhythmic movements of discrete muscle groups and are formed due to genetic mutation that disrupts the production of histamine in the brain and are primarily caused due to the disturbance in the balance of neurotransmitters in the brain, which carry nerve signals from cell to cell. Tourette syndrome also increases the risk of hyperactivity disorder or obsessive-compulsive disorder in children. Blinking, frowning, jerking, and foot stamping are some of the additional symptoms of Tourette's syndrome.

The disease:

  • primarily affects children aged between 6 years and 17 years with the average onset age of 3 and 9 years;
  • occurs in people from all ethnic groups;
  • occurs in males 3 to 4 times more often than females;
  • is twice as likely in Non-Hispanic white children tan in Hispanic and non-Hispanic black children.

The U.S. dominates the global Tourette syndrome market where, as per the data of the CDC study, 1 of every 360 (0.3%) children 6-17 years of age have received a diagnosis of TS, and that incidence rate is expected to expand in the future. Europe is the second-largest market and is expanding there owing to its high incidence rate and is also expanding in the Asia Pacific and Latin America due to increasing awareness among patients.

There are currently no commercially approved drugs for the treatment of Tourette's Syndrome in the market but, as mentioned above, many companies are working on the research and development of new drugs to treat the disease (e.g. AstraZeneca Plc, Boehringer Ingelheim International GmbH, Eli Lilly and Co., Mylan NV, Otsuka Holdings Co. Ltd., Pfizer Inc., Sun Pharmaceutical Industries Ltd., Neurocrine Biosciences, Inc., Novartis AG, Teva Pharmaceutical Industries Ltd.) so the drug pipeline is quite robust, and many drugs are expected to launch during the period of forecast (2020-2027).

Technavio has estimated that the global Tourette's Syndrome drugs market will progress at a CAGR of 5% ($98.77M) over the next few years suggesting that the size of the drug market is approximately $40B. Were SciSprac's SCI-110 product eventually approved by the FDA a modest 0.5% share of that market would equate to potential revenue of approximately $200M annually although such a possibility would not materialize until the end of the decade at the earliest.

SCI-110: Obstructive Sleep Apnea

Sleep apnea is a common sleep disorder that affects millions of people in the world. It takes its name from the Greek word apnea, which means "without breath." People with sleep apnea literally stop breathing repeatedly during their sleep, often for a minute or longer and as many as hundreds of times during a single night. It occurs when the muscles relax during sleep, causing soft tissue in the back of the throat to collapse and block the upper airway which may be caused by either complete obstruction of the airway (obstructive apnea) or partial obstruction which can both wake one up. Of these, obstructive sleep apnea (OSA) is the most common.

The disease is more prevalent in individuals with factors that include:

  • being older,
  • being male,
  • being a minority race,
  • having a high body mass index,
  • having a large neck circumference,
  • having craniofacial abnormalities,
  • being menopausal, and
  • having health behaviors such as smoking and alcohol use.

The standard therapy of continuous positive airway pressure (CPAP) is efficient in improving OSA and in reducing its associated comorbidities but patients often cannot tolerate CPAP, which can produce general discomfort or troublesome nasal symptoms leading to poor adherence.  As such, alternative options need to be developed and pharmacological therapies are an obvious approach. Furthermore, Frost & Sullivan estimates the prevalence of OSA to be 12% or 29.4 million of the U.S. adult population with nearly 80% of the population undiagnosed which demonstrates the unmet medical need.

The global Obstructive Sleep Apnea market size was found to be US$221.8M in 2017 of which the USA accounted for 75%. The market is estimated to be increasing by 4.7% CAGR during the study period (2017–2030) which would put the market size at approximately US$400M by 2030. Were SciSprac's SCI-110 product eventually approved by the FDA a modest 0.5% share of that market would equate to potential revenue of only $2M annually although such a possibility would not materialize until the end of the decade at the earliest.

View single page >> |

Disclosure: This article is part of a new “UnderCovered” series of exclusive articles featuring companies with limited coverage. Authors are compensated by TalkMarkets for their time ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.
Alpha Stockman 1 month ago Member's comment

Good read, thanks.

William K. 1 month ago Member's comment

Quite a serious bit of coverage and analysis in this article. Thanks.

Bill Johnson 1 month ago Member's comment

Agreed. Nice to see.

Terrence Howard 1 month ago Member's comment

Sounds promising.

Joel Santiago 1 month ago Member's comment

When will CannAmide be available outside of Canada?

Adam Reynolds 1 month ago Member's comment

Why is there nothing on SciSparc's website? Unless there is something wrong with my internet, every page is blank except for the homepage, and that is practically blank.


Kurt Benson 1 month ago Member's comment

Thanks for putting $SPRCY on my radar!